US, EU Nods For Gilead's Vemlidy To Enter Saturated Hep B Market
Executive Summary
Vemlidy, Gilead Sciences' follow-on to blockbuster hepatitis B product treatment Viread, has this week won approval in the US and been given the green light for approval in Europe – vital steps in Gilead's long term plan to protect its hep B portfolio from generic erosion.
You may also be interested in...
In Hep B, Functional Cure Likely Means Two-Part Combination Process
While current HBV drugs work well to suppress the virus, combination success in HIV and HCV is leading biopharmas to seek a multi-part approach to suppressing and clearing the virus, with limited-term therapy.
Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues
Gilead CEO John Milligan, pressured by an analyst, gave a brief rundown of the company's strategic priorities as investors wait for the company to spend its $34bn in cash on revenue-increasing opportunities to offset declining hepatitis C drug sales.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.